ClinicalTrials.gg
WithdrawnNCT01193166Updated Jul 8, 2013

Twelve Month Study Comparing Paliperidone Palmitate and Select Oral Antipsychotics in Adults With Schizophrenia Who Have Been Recently Discharged From an Inpatient Psychiatric Hospital

A Phase 4 interventional study of paliperidone palmitate and risperidone in Schizophrenia, sponsored by Ortho-McNeil Janssen Scientific Affairs, LLC. Withdrawn. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2013-07-08.

Sponsored by Ortho-McNeil Janssen Scientific Affairs, LLC (part of Johnson & Johnson) · Phase 4, Interventional, and Prevention

Why this study was withdrawn
This study was stopped due to an internal reconsideration of priorities of the product portfolio.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 115 studies testing paliperidone in Schizophrenia — 6 open to participants now, 6 under way, none of them phase 3. paliperidone · Schizophrenia.

Enrollment
114th of 115
0 · median 178
Started
2010
with 7 others
Phase 4
42 of 115
5 open now
Registered
59th of 115
by date

Among the 115 studies testing paliperidone in Schizophrenia, this one is the 114th largest by enrollment, is one of 8 that started in 2010, is one of 42 in phase 4, and was the 59th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

6 of the 115 studies testing paliperidone in Schizophrenia are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About paliperidone

paliperidone: first FDA approval 2006 (INVEGA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies testing paliperidone in Schizophrenia, or all of them as a file.
02

Study summary

The study will assess the use of paliperidone palmitate compared with oral antipsychotic treatment in delaying time to a protocol-defined treatment failure over 12 months, in patients diagnosed with schizophrenia who were recently released from an inpatient psychiatric hospital.

Read the detailed description

The primary objective of this study will be to compare paliperidone palmitate treatment with the randomly assigned oral antipsychotic treatment in delaying time to treatment failure over 12 months in subjects diagnosed with schizophrenia who were recently discharged from an inpatient psychiatric hospital. Patients will receive either paliperidone palmitate 78, 117, 156, or 234 mg monthly by injection for twelve months OR oral aripiprazole, haloperidol, olanzapine, paliperidone, perphenazine, quetiapine, and risperidone at doses selected by the study doctor.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
  • Risperidone
  • Risperdal
  • Paliperidone palmitate
  • Aripiprazole
  • Haloperidol
  • Olanzapine
  • Paliperidone
  • Perphenazine
  • Quetiapine
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be able to understand and sign the form approved by the Institutional Review Board (IRB)
  • Must be an outpatient who, following an acute exacerbation of schizophrenia, has been discharged from an inpatient psychiatric hospital within 60 days of screening
  • Have a current diagnosis of schizophrenia
  • Have available a designated individual who is likely to have knowledge of the subject's health status and who agrees to let the study site personnel know of changes in the patient's circumstances
  • Women must be (for at least 2 years), surgically sterile (hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy), abstinent, or if sexually active, be practicing a highly effective method of

Exclusion criteria

Exclusion Criteria:

  • Allergies, (anaphylaxis-type reaction), or intolerance to risperidone or paliperidone
  • Actively abusing intravenous drugs
  • Have a positive urine drug screen test for barbiturates, cocaine, amphetamines, or opiates at screening
  • have an unstable medical illness
  • Women who are pregnant or breast-feeding, or planning to become pregnant
  • Have received injectable antipsychotic treatment within 2 injection cycles prior to screening
  • Received treatment with clozapine within 3 months of screening
  • Attempted suicide within 6 months before screening or are at imminent risk of suicide or violent behavior, as clinically assessed by the investigator at time of screening
  • homeless at time of stuyd consent
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    001

    paliperidone palmitate 78 117 156 or 234 mg monthly injection for 12 months

    Drug: paliperidone palmitate

  • Active comparator
    002

    olanzapine flexible dosing as prescribed by the study doctor for 12 months

    Drug: olanzapine

  • Active comparator
    003

    paliperidone flexible dosing as prescribed by the study doctor for 12 months

    Drug: paliperidone

  • Active comparator
    004

    aripiprazole flexible dosing as prescribed by the study doctor for 12 months

    Drug: aripiprazole

  • Active comparator
    005

    haloperidole flexible dosing as prescribed by the study doctor for 12 months

    Drug: haloperidole

  • Active comparator
    006

    perphenazine flexible dosing as prescribed by the study doctor for 12 months

    Drug: perphenazine

  • Active comparator
    007

    quetiapine flexible dosing as prescribed by the study doctor for 12 months

    Drug: quetiapine

  • Active comparator
    008

    risperidone flexible dosing as prescribed by the study doctor for 12 months

    Drug: risperidone

Interventions

  • 78, 117, 156, or 234 mg monthly injection for 12 months

  • flexible dosing as prescribed by the study doctor for 12 months

  • flexible dosing as prescribed by the study doctor for 12 months

  • flexible dosing as prescribed by the study doctor for 12 months

  • flexible dosing as prescribed by the study doctor for 12 months

  • flexible dosing as prescribed by the study doctor for 12 months

  • flexible dosing as prescribed by the study doctor for 12 months

  • flexible dosing as prescribed by the study doctor for 12 months

06

What researchers measure

Primary outcomes

  1. Time to treatment failure defined as psychiatric hospitalization, suicide, discontinuation of treatment due to inadequate efficacy or safety/tolerability, treatment supplementation due to inadequate efficacy, or increase in psychiatric services

    Time frame: Up to 12 months

Secondary outcomes

  1. Change in Clinical Global Impression-Severity score

    Time frame: Up to 12 months

  2. Change in Global Assessment of Functionality score

    Time frame: Up to 12 months

  3. Change in Medication Satisfaction Questionnaire score

    Time frame: Up to 12 months

  4. Proportion of subjects with at least one psychiatric hospitalization

    Time frame: Up to 12 months

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2010, a primary completion of Sep 2012 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2010
First posted
Sep 1, 2010
Start
Aug 2010
Primary completionEst.
Sep 2012
CompletionEst.
Sep 2012
Last update
Jul 8, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01193166
Responsible party
Sponsor
First posted
Sep 1, 2010
Start date
Aug 2010
Primary completion
Sep 2012 (estimated)
Completion
Sep 2012 (estimated)
Last update
Jul 8, 2013

Study contacts

Ortho-McNeil Janssen Scientific Affairs, LLC Clinical Trial
study director · Ortho-McNeil Janssen Scientific Affairs, LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paliperidone

Start the discussion